Plain-English translation of NCT07267949 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, can help reduce how often irregular heartbeats occur in people with atrial fibrillation. About 200 participants will be randomly assigned to take either different doses of this medication or a placebo (inactive pill) twice daily for 12 weeks. The trial will measure how well the medication works and how safe it is.
Atrial fibrillation can cause symptoms like palpitations, fatigue, and increases stroke risk. Researchers are developing this medication to offer patients another option for controlling their irregular heartbeats.
You likely qualify if…
You likely don't qualify if…
You would participate for about 20 weeks total: a 4-week screening period, 12 weeks of treatment, and a 30-day follow-up. During this time, you would take a tablet twice daily (either the new medication at one of several doses or a placebo). You would have a small heart monitoring device implanted, attend several clinic visits for blood and urine tests and heart tracings, and have your heart rhythm tracked throughout the trial.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Bulgaria